Matteo Morotti
@MMorotti
Followers
489
Following
7K
Media
11
Statuses
568
Gynaecologist, Clinician Scientist, @chuvlausanne. Immuno and cell therapy. Supporter @genoacfc 🇮🇹➡️🏴➡️🇨🇭Tweets my own
Lausanne, Switzerland
Joined November 2011
RT @WeizmannScience: We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of I….
0
35
0
RT @LabWaggoner: Review @NatRevImmunol @CoukosGeorge.Tumor-associated vasculature in T cell homing and immunity: opportunities for cancer t….
nature.com
Nature Reviews Immunology - The vasculature that forms in tumours and supports tumour growth is abnormal and limits T cell entry into tumours. Here, the authors review how the tumour vasculature...
0
18
0
RT @herbloong: #foodforthought 🍔🍕🍪🤔: the impact of infusion time of #ICIs is huge! ⏰ How many of our #immune checkpoint inhibitor clinical….
0
11
0
RT @SuyogCancer: 📊 Who’s on the podium at #ASCO?.Audit of 1563 oral presentations (2021–24) reveals:.🇺🇸 USA – 66.7%.🇨🇳 China – 6.3%.🇫🇷 Fran….
0
32
0
RT @ESGO_society: The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence….
0
20
0
RT @zhi_yuan_hu: CIDER now works with Seurat v5! 🎉 CIDER helps evaluate scRNA-seq integration, and we’ve updated it for the latest version.….
0
1
0
RT @NatRevDrugDisc: Novel strategies to manage CAR-T cell toxicity This new Review discusses management of safety….
0
112
0
RT @GillSharlene: #GI25 @ASCO .🌟 Practice-changing ALASCCA ph3 trial 🇸🇪.📌 ASA 160mg in PIK3CA+ stage II-III #CRCsm.📌 PIK3CA+ in 37%.➡️ HR 0….
0
32
0
RT @SwingleKelsey: Thrilled to share our recent work out today in @Nature on an mRNA therapeutic to treat pre-eclampsia! This work has been….
nature.com
Nature - A platform for mRNA lipid nanoparticle delivery to the placenta to treat pre-eclampsia is shown to improve fetal and maternal health in mice and has potential clinical applications in...
0
37
0
RT @OvarianCancerUK: A vaccine to prevent ovarian cancer? 🧬. It’s in the works at @Oxford and patients are helping shape it. Read how our….
ovarian.org.uk
Groundbreaking research funded by Ovarian Cancer Action has received a major boost from Cancer Research UK to develop the world’s first vaccine to prevent ovarian cancer. Discover how this innovative...
0
14
0
RT @CellPressNews: We’re excited to announce a two-day #LabLinks on Tumor immunotherapy and immunology, organized by scientists @Ludwig_Can….
0
3
0
RT @LabWaggoner: Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma @ImmunityCP @CoukosGeorge….
0
8
0
RT @CDRLifeBiotech: #NEWS: CDR-Life hits major milestones in cancer immunotherapy!.✅ First patient dosed with CDR404 (MAGE-A4 target).✅ CDR….
0
1
0
RT @OncoUNILCHUV: 🟢NEW REVIEW @NatRevClinOncol where @EleonoraGhisoni @MMorotti @CoukosGeorge & al. propose the implementation of systemat….
0
1
0
A big thank to @CoukosGeorge @DenardaD @EleonoraGhisoni @AlizeeGrimm and all others from @OncoUNILCHUV that contributed to.discussions and ideas!.
0
0
1
However, the integration of these technologies into a real-world clinical setting is a challenging task. Here we proposed that implementing the immunophenotype using simple immunohistochemistry could be a first step towards this direction.
1
0
1
The development of multimodal biomarkers, including those that assess tissue spatial organisation (e.g., computational pathology) may enable the development of rational anticancer drug combinations, potentially driving deeper and more durable responses. 2.
1
0
0
Pleased to share our review on immunotherapy in ovarian cancer where we share our thoughts for the implementation of a systematic CD8+ T cell-based immunophenotypic classification of this malignancy to tailor immunotherapy combinations…1.
2
2
12
RT @LivnatJerby: Our new #paper is out in @NatImmunol. Applying #spatial transcriptomics at subcellular resolution to 130 ovarian #cancer t….
nature.com
Nature Immunology - Here the authors provide a resource for ovarian cancer combining spatial transcriptomics, genomics, CRISPR Perturb-seq screens and in silico methods to focus on T cells and...
0
58
0